Autopsy report · NCT05164471
Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B
Cause of deathFunding or business
“Freeline has decided to pause development of FLT180a for business priorities”
Life of this trial
- Ran for about 1 year 6 months before it stopped.
- 6 participants enrolled.
- Results were posted on the registry 3 years 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Spur Therapeutics
- Sponsor type
- Industry
- Conditions
- Hemophilia B
- Interventions
- verbrinacogene setparvovec
- Participants
- 6
- Sites
- 7
- Countries
- United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.